{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:40:28Z","timestamp":1782513628101,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Canadian Network for Research on Vasculitides"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10067-021-05643-5","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T18:20:18Z","timestamp":1613154018000},"page":"3207-3217","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Characterization of visual manifestations and identification of risk factors for permanent vision loss in patients with giant cell arteritis"],"prefix":"10.1007","volume":"40","author":[{"given":"Hussein","family":"Baalbaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darya","family":"Jalaledin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Lachance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Febrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Rh\u00e9aume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4523-8525","authenticated-orcid":false,"given":"Jean-Paul","family":"Makhzoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"issue":"10","key":"5643_CR1","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/art.24459","volume":"61","author":"MA Gonzalez-Gay","year":"2009","unstructured":"Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA, Gonzalez-Juanatey C, Martin J, Llorca J (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61(10):1454\u20131461. https:\/\/doi.org\/10.1002\/art.24459","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5643_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees AJ, Scott DGI, Specks U, Stone JH, Takahashi K, Watts RA (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1\u201311. https:\/\/doi.org\/10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5643_CR3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/rheumatology\/kew273","volume":"56","author":"C Dejaco","year":"2017","unstructured":"Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B (2017) The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford) 56(4):506\u2013515. https:\/\/doi.org\/10.1093\/rheumatology\/kew273","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"5643_CR4","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/01.md.0000180042.42156.d1","volume":"84","author":"MA Gonzalez-Gay","year":"2005","unstructured":"Gonzalez-Gay MA, Barros S, Lopez-Diaz MJ, Garcia-Porrua C, Sanchez-Andrade A, Llorca J (2005) Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 84(5):269\u2013276. https:\/\/doi.org\/10.1097\/01.md.0000180042.42156.d1","journal-title":"Medicine (Baltimore)"},{"issue":"12","key":"5643_CR5","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s00417-016-3434-7","volume":"254","author":"E De Smit","year":"2016","unstructured":"De Smit E, O'Sullivan E, Mackey DA, Hewitt AW (2016) Giant cell arteritis: ophthalmic manifestations of a systemic disease. Graefes Arch Clin Exp Ophthalmol 254(12):2291\u20132306. https:\/\/doi.org\/10.1007\/s00417-016-3434-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"suppl_2","key":"5643_CR6","doi-asserted-by":"publisher","first-page":"ii63","DOI":"10.1093\/rheumatology\/kex428","volume":"57","author":"I Vodopivec","year":"2018","unstructured":"Vodopivec I, Rizzo JF 3rd (2018) Ophthalmic manifestations of giant cell arteritis. Rheumatology (Oxford) 57(suppl_2):ii63\u2013ii72. https:\/\/doi.org\/10.1093\/rheumatology\/kex428","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"5643_CR7","doi-asserted-by":"publisher","first-page":"e774","DOI":"10.1016\/S2665-9913(20)30222-8","volume":"2","author":"R Chu","year":"2020","unstructured":"Chu R, Foster C, Ali M, Chaba T, Clifford AH, Mahr A, Soo J, Cohen Tervaert JW, Yacyshyn E (2020) Optimal length and usefulness of temporal artery biopsies in the diagnosis of giant cell arteritis: a 10-year retrospective review of medical records. Lancet Rheumatol 2(12):e774\u2013e778. https:\/\/doi.org\/10.1016\/S2665-9913(20)30222-8","journal-title":"Lancet Rheumatol"},{"issue":"2 Suppl 89","key":"5643_CR8","first-page":"S-103-6","volume":"33","author":"P Patil","year":"2015","unstructured":"Patil P, Williams M, Maw WW et al (2015) Fast track pathway reduces sight loss in giant cell arteritis: results of a longitudinal observational cohort study. Clin Exp Rheumatol 33(2 Suppl 89):S-103-6","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"5643_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1136\/annrheumdis-2017-212649","volume":"77","author":"C Dejaco","year":"2018","unstructured":"Dejaco C, Ramiro S, Duftner C, Besson FL, Bley TA, Blockmans D, Brouwer E, Cimmino MA, Clark E, Dasgupta B, Diamantopoulos AP, Direskeneli H, Iagnocco A, Klink T, Neill L, Ponte C, Salvarani C, Slart RHJA, Whitlock M, Schmidt WA (2018) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 77(5):636\u2013643. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212649","journal-title":"Ann Rheum Dis"},{"issue":"suppl_2","key":"5643_CR10","doi-asserted-by":"publisher","first-page":"ii22","DOI":"10.1093\/rheumatology\/kex461","volume":"57","author":"WA Schmidt","year":"2018","unstructured":"Schmidt WA (2018) Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology (Oxford) 57(suppl_2):ii22\u2013ii31. https:\/\/doi.org\/10.1093\/rheumatology\/kex461","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5643_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/art.39824","volume":"69","author":"M Rh\u00e9aume","year":"2017","unstructured":"Rh\u00e9aume M, Rebello R, Pagnoux C, Carette S, Clements-Baker M, Cohen-Hallaleh V, Doucette-Preville D, Stanley Jackson B, Salama Sargious Salama S, Ioannidis G, Khalidi NA (2017) High-resolution magnetic resonance imaging of scalp arteries for the diagnosis of giant cell arteritis: results of a prospective cohort study. Arthritis Rheum 69(1):161\u2013168. https:\/\/doi.org\/10.1002\/art.39824","journal-title":"Arthritis Rheum"},{"issue":"14","key":"5643_CR12","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1097\/MD.0000000000000622","volume":"94","author":"M Soussan","year":"2015","unstructured":"Soussan M, Nicolas P, Schramm C, Katsahian S, Pop G, Fain O, Mekinian A (2015) Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. Medicine (Baltimore) 94(14):e622. https:\/\/doi.org\/10.1097\/MD.0000000000000622","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"5643_CR13","doi-asserted-by":"publisher","first-page":"e274","DOI":"10.7417\/CT.2018.2092","volume":"169","author":"M Baymakova","year":"2018","unstructured":"Baymakova M, Demirev A, Kostadinova I, Andonova R, Popov GT, Plochev K (2018) Giant-cell arteritis without cranial manifestations presenting as fever of unknown origin: a diagnostic value of 18F-FDG PET\/CT. Clin Ter 169(6):e274\u2013e276. https:\/\/doi.org\/10.7417\/CT.2018.2092","journal-title":"Clin Ter"},{"key":"5643_CR14","doi-asserted-by":"publisher","first-page":"687608","DOI":"10.1155\/2014\/687608","volume":"2014","author":"H Balink","year":"2014","unstructured":"Balink H, Bennink RJ, van Eck-Smit BL, Verberne HJ (2014) The role of 18F-FDG PET\/CT in large-vessel vasculitis: appropriateness of current classification criteria? Biomed Res Int 2014:687608\u2013687613. https:\/\/doi.org\/10.1155\/2014\/687608","journal-title":"Biomed Res Int"},{"issue":"8","key":"5643_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/art.40864","volume":"71","author":"AM Sammel","year":"2019","unstructured":"Sammel AM, Hsiao E, Schembri G, Nguyen K, Brewer J, Schrieber L, Janssen B, Youssef P, Fraser CL, Bailey E, Bailey DL, Roach P, Laurent R (2019) Diagnostic accuracy of positron emission tomography\/computed tomography of the head, neck, and chest for giant cell arteritis: a prospective, double-blind, cross-sectional study. Arthritis Rheum 71(8):1319\u20131328. https:\/\/doi.org\/10.1002\/art.40864","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5643_CR16","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1097\/01.md.0000145369.25558.b5","volume":"83","author":"MA Gonzalez-Gay","year":"2004","unstructured":"Gonzalez-Gay MA, Pi\u00f1eiro A, Gomez-Gigirey A, Garcia-Porrua C, Pego-Reigosa R, Dierssen-Sotos T, Llorca J (2004) Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 83(6):342\u2013347. https:\/\/doi.org\/10.1097\/01.md.0000145369.25558.b5","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"5643_CR17","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1093\/rheumatology\/keaa058","volume":"59","author":"A Ho\u010devar","year":"2020","unstructured":"Ho\u010devar A, Je\u0161e R, Tom\u0161i\u010d M, Rotar \u017d (2020) Risk factors for severe cranial ischaemic complications in giant cell arteritis. Rheumatology (Oxford) 59(10):2953\u20132959. https:\/\/doi.org\/10.1093\/rheumatology\/keaa058","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5643_CR18","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/01.md.0000119761.27564.c9","volume":"83","author":"G Nesher","year":"2004","unstructured":"Nesher G, Berkun Y, Mates M, Baras M, Nesher R, Rubinow A, Sonnenblick M (2004) Risk factors for cranial ischemic complications in giant cell arteritis. Medicine (Baltimore) 83(2):114\u2013122. https:\/\/doi.org\/10.1097\/01.md.0000119761.27564.c9","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"5643_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.semarthrit.2019.09.008","volume":"50","author":"A Dumont","year":"2020","unstructured":"Dumont A, Lecannuet A, Boutemy J, Maign\u00e9 G, Martin-Silva N, Deshayes S, Audemard-Verger A, Sultan A, Planchard G, Aouba A, de Boysson H (2020) Characteristics and outcomes of patients with ophthalmologic involvement in giant-cell arteritis: a case-control study. Semin Arthritis Rheum 50(2):335\u2013341. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.09.008","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"5643_CR20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3899\/jrheum.151033","volume":"43","author":"M Saleh","year":"2016","unstructured":"Saleh M, Turesson C, Englund M, Merkel PA, Mohammad AJ (2016) Visual complications in patients with biopsy-proven giant cell arteritis: a population-based study. J Rheumatol 43(8):1559\u20131565. https:\/\/doi.org\/10.3899\/jrheum.151033","journal-title":"J Rheumatol"},{"issue":"2","key":"5643_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/rheumatology\/36.2.251","volume":"36","author":"C Font","year":"1997","unstructured":"Font C, Cid MC, Coll-Vinent B, L\u00f3pez-Soto A, Grau JM (1997) Clinical features in patients with permanent visual loss due to biopsy-proven giant cell arteritis. Br J Rheumatol 36(2):251\u2013254. https:\/\/doi.org\/10.1093\/rheumatology\/36.2.251","journal-title":"Br J Rheumatol"},{"issue":"8","key":"5643_CR22","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1002\/art.1780330810","volume":"33","author":"GG Hunder","year":"1990","unstructured":"Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT, McShane DJ, Mills JA, Wallace SL, Zvaifler NJ (1990) The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 33(8):1122\u20131128. https:\/\/doi.org\/10.1002\/art.1780330810","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5643_CR23","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.ophtha.2005.01.036","volume":"112","author":"H Danesh-Meyer","year":"2005","unstructured":"Danesh-Meyer H, Savino PJ, Gamble GG (2005) Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 112(6):1098\u20131103. https:\/\/doi.org\/10.1016\/j.ophtha.2005.01.036","journal-title":"Ophthalmology"},{"issue":"4","key":"5643_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1034\/j.1600-0420.2002.800403.x","volume":"80","author":"SS Hayreh","year":"2020","unstructured":"Hayreh SS, Zimmerman B, Kardon RH (2020) Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 80(4):355\u2013367. https:\/\/doi.org\/10.1034\/j.1600-0420.2002.800403.x","journal-title":"Acta Ophthalmol Scand"},{"issue":"2","key":"5643_CR25","first-page":"61","volume":"37 Suppl 117","author":"M Czihal","year":"2019","unstructured":"Czihal M, Tschaidse J, Bernau C et al (2019) Ocular ischaemic complications in giant cell arteritis: CHADS2-score predicts risk of permanent visual impairment. Clin Exp Rheumatol 37 Suppl 117(2):61\u201364","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"5643_CR26","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/s0002-9343(01)00770-7","volume":"111","author":"E Liozon","year":"2001","unstructured":"Liozon E, Herrmann F, Ly K, Robert PY, Loustaud V, Soria P, Vidal E (2001) Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 111(3):211\u2013217. https:\/\/doi.org\/10.1016\/s0002-9343(01)00770-7","journal-title":"Am J Med"},{"issue":"7","key":"5643_CR27","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.3899\/jrheum.151135","volume":"43","author":"E Liozon","year":"2016","unstructured":"Liozon E, Dalmay F, Lalloue F, Gondran G, Bezanahary H, Fauchais AL, Ly KH (2016) Risk factors for permanent visual loss in biopsy-proven giant cell arteritis: a study of 339 patients. J Rheumatol 43(7):1393\u20131399. https:\/\/doi.org\/10.3899\/jrheum.151135","journal-title":"J Rheumatol"},{"issue":"4","key":"5643_CR28","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/art.20171","volume":"50","author":"G Nesher","year":"2004","unstructured":"Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M (2004) Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50(4):1332\u20131337. https:\/\/doi.org\/10.1002\/art.20171","journal-title":"Arthritis Rheum"},{"issue":"10","key":"5643_CR29","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1002\/art.22141","volume":"54","author":"MS Lee","year":"2006","unstructured":"Lee MS, Smith SD, Galor A, Hoffman GS (2006) Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54(10):3306\u20133309. https:\/\/doi.org\/10.1002\/art.22141","journal-title":"Arthritis Rheum"},{"issue":"8","key":"5643_CR30","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.autrev.2014.02.006","volume":"13","author":"VM Mart\u00ednez-Taboada","year":"2014","unstructured":"Mart\u00ednez-Taboada VM, L\u00f3pez-Hoyos M, Narvaez J, Mu\u00f1oz-Cacho P (2014) Effect of antiplatelet\/anticoagulant therapy on severe ischemic complications in patients with giant cell arteritis: a cumulative meta-analysis. Autoimmun Rev 13(8):788\u2013794. https:\/\/doi.org\/10.1016\/j.autrev.2014.02.006","journal-title":"Autoimmun Rev"},{"issue":"3","key":"5643_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1093\/rheumatology\/kez664","volume":"59","author":"SL Mackie","year":"2020","unstructured":"Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, Mahr A, Mukhtyar C, Reynolds G, de Souza AWS, Brouwer E, Bukhari M, Buttgereit F, Byrne D, Cid MC, Cimmino M, Direskeneli H, Gilbert K, Kermani TA, Khan A, Lanyon P, Luqmani R, Mallen C, Mason JC, Matteson EL, Merkel PA, Mollan S, Neill L, Sullivan EO\u2019, Sandovici M, Schmidt WA, Watts R, Whitlock M, Yacyshyn E, Ytterberg S, Dasgupta B (2020) British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology (Oxford) 59(3):487\u2013494. https:\/\/doi.org\/10.1093\/rheumatology\/kez664","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5643_CR32","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/rheumatology\/ken465","volume":"48","author":"C Salvarani","year":"2009","unstructured":"Salvarani C, Della Bella C, Cimino L et al (2009) Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. Rheumatology (Oxford) 48(3):250\u2013253. https:\/\/doi.org\/10.1093\/rheumatology\/ken465","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5643_CR33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","volume":"41","author":"MC Cid","year":"1998","unstructured":"Cid MC, Font C, Oristrell J, de la Sierra A, Coll-Vinent B, L\u00f3pez-Soto A, Vilaseca J, Urbano-M\u00e1rquez A, Grau JM (1998) Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 41(1):26\u201332. https:\/\/doi.org\/10.1002\/1529-0131(199801)41:1<26::AID-ART4>3.0.CO;2-0","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"5643_CR34","doi-asserted-by":"publisher","first-page":"S294","DOI":"10.1086\/513856","volume":"179","author":"CA Dinarello","year":"1999","unstructured":"Dinarello CA (1999) Cytokines as endogenous pyrogens. J Infect Dis 179(Suppl 2):S294\u2013S304. https:\/\/doi.org\/10.1086\/513856","journal-title":"J Infect Dis"},{"issue":"20","key":"5643_CR35","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1073\/pnas.84.20.7251","volume":"84","author":"J Gauldie","year":"1987","unstructured":"Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H (1987) Interferon beta 2\/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci U S A 84(20):7251\u20137255. https:\/\/doi.org\/10.1073\/pnas.84.20.7251","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"5643_CR36","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1161\/01.CIR.0000066907.83923.32","volume":"107","author":"J Hern\u00e1ndez-Rodr\u00edguez","year":"2003","unstructured":"Hern\u00e1ndez-Rodr\u00edguez J, Segarra M, Vilardell C et al (2003) Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant-cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107(19):2428\u20132434. https:\/\/doi.org\/10.1161\/01.CIR.0000066907.83923.32","journal-title":"Circulation"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05643-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05643-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05643-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T20:08:03Z","timestamp":1626725283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05643-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["5643"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05643-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"27 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Approval from the center\u2019s research ethics board (REB) was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Dr. Makhzoum reports personal fees from Hoffmann-La Roche, outside the submitted work. No other disclosures relevant to this article were reported.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}